rxstat › Classes › Anti-dementia Drugs

Anti-dementia Drugs: shortage status in Canada

3 of the 4 anti-dementia drugs rxstat tracks are currently in shortage in Canada. When one drug in a class is short, demand often shifts to its alternatives, so related drugs can tighten too; each page below shows which manufacturers are affected and the latest recovery estimates.

Donepezil (Aricept Rdt) Partial shortage 14 of 39 reported products affected · est. return Oct 23, 2026 Memantine (Ebixa) Partial shortage 2 of 13 reported products affected · est. return Aug 20, 2026 Rivastigmine (Exelon) Partial shortage 1 of 30 reported products affected Galantamine No current shortage

Guides: what to do when your medication is in shortage · how to read these statuses

Class groupings follow the WHO ATC classification in Health Canada's reports. Data reflects manufacturer mandatory filings; see methodology.